Filing Details

Accession Number:
0001127602-12-029087
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-10-25 18:32:55
Reporting Period:
2012-10-24
Filing Date:
2012-10-25
Accepted Time:
2012-10-25 18:32:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1185618 W Kevin Sharer One Amgen Center Drive
Thousand Oaks CA 91320-1799
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-10-24 1,391 $71.88 102,409 No 4 M Direct
Common Stock Acquisiton 2012-10-24 193,609 $71.88 296,018 No 4 M Direct
Common Stock Acquisiton 2012-10-24 195,000 $0.00 268,494 No 5 G Indirect Living Trust
Common Stock Disposition 2012-10-24 195,000 $0.00 101,018 No 5 G Direct
Common Stock Disposition 2012-10-24 235,495 $88.06 32,999 No 4 S Indirect Living Trust
Common Stock Disposition 2012-10-24 27,505 $88.72 5,494 No 4 S Indirect Living Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 5 G Indirect Living Trust
No 5 G Direct
No 4 S Indirect Living Trust
No 4 S Indirect Living Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Iso (Right to Buy) Disposition 2012-10-24 1,391 $0.00 1,391 $71.88
Common Stock Nqso (Right to Buy) Disposition 2012-10-24 193,609 $0.00 193,609 $71.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-04-03 2013-04-03 No 4 M Direct
0 2007-04-03 2013-04-03 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,434 Indirect By 401(k) Plan
Footnotes
  1. These shares are being transferred to the reporting person's Living Trust.
  2. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 9,250 RSUs which fully vest on 4/28/2013; 22,750 RSUs which vest in two equal annual installments of 11,375 each commencing 4/26/2013; 60,000 RSUs which vest in two equal installments of 19,800 each on 4/25/2013 and 4/25/2014 and one installment of 20,400 on 4/25/2015; and 8,933 RSUs which vest in three installments of 2,947, 2,948 and 3,038 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.
  3. These shares include 85 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
  4. The price reported is an average price. The prices ranged from $87.62 to $88.61 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  5. The price reported is an average price. The prices ranged from $88.62 to $89.11 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  6. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.